Why the study?
Does diflunisal inhibit platelet function and increase fecal blood loss less than aspirin in normal subjects?
Does diflunisal inhibit platelet function and increase fecal blood loss less than aspirin in normal subjects?
Diflunisal inhibits platelet function and increases fecal blood loss to a lesser extent and for a shorter duration than comparable doses of aspirin.
Answers are grounded in this paper and cite their sources.
Diflunisal may be preferable to aspirin when minimizing platelet inhibition or GI blood loss; confirms lesser effects in this RCT.
The effects of diflunisal, a nonacetylated difluorinated salicylate, on platelet function were compared with those of aspirin and placebo. In a randomized, double-blind trial, normal subjects were given diflunisal, 250, 500, or 1,000 mg twice daily; aspirin, 650 or 1,300 mg twice daily; or placebo for 8-day periods. Diflunisal, 250 mg, had no effect on platelet function, whereas 500 mg induced minimal inhibition of collagen-induced release of platelet serotonin, and 1,000 mg inhibited platelet malondialdehyde production, moderately prolonged template bleeding times (p = NS), and increased fecal blood loss (p < 0.05). In contrast, aspirin, 650 mg, markedly inhibited collagen-induced platelet aggregation and serotonin release, and 1,300 mg prolonged bleeding time (p < 0.01) and increased fecal blood loss (p < 0.01). The effects of aspirin lasted for up to 5 days, whereas changes induced by diflunisal had returned to baseline 24 hours after the drug was discontinued. We conclude that in doses in the same range as those of aspirin diflunisal inhibits platelet function less.
No takes yet. Share an insight, caveat, or question.
Green et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: